Modelling is an essential part of health economic analyses. It is a central tool for authorities, experts and payers to support decision-making regarding healthcare resource utilization.
Modelling is an essential part of health economic analyses. It is a central tool for authorities, experts and payers to support decision-making regarding healthcare resource utilization. With the help of modelling, fragmented research data, observations, and experiences, as well as justified assumptions, are compiled into a synthesis that aims to anticipate and predict the impact of healthcare interventions on individuals, patient groups, healthcare and society.
Modelling not only answers the decision maker’s question about the most likely outcome, but also the probability of extreme scenarios, as well as the credible range of results. In its most general form, modelling relates to the cost-effectiveness of an intervention. This means that the costs are examined together with the health benefits of the intervention. Another common target of modelling is the budget impact of an intervention. In this case, the focus is on the intervention’s impact on the use of resources. These can be even directly related to the intervention, or indirectly to the entire treatment path of a patient.
Medaffcon has the ability to complete modelling projects from the localization of the customer’s ready global core models to the comprehensive construction of models from the beginning. We have been doing modelling for over 10 years, providing our customers with an effective tool to support decision making.
“Modeling enables the combination of information from multiple sources and thus the evaluation of effectiveness and cost-effectiveness. The analysis can be based on any kind of information, such as the results of clinical trials or real world data.”
“The purpose of modelling is to provide tools for the clients and decision makers for managing and predicting future uncertainty. Modelling provides information for decision-making and for discussions with public authorities and healthcare payers.”
Read more about our interactive value tools that combine health economic modelling, real world evidence and data science into one easy to use product.
Are you employed in the pharmaceutical industry and seeking insights into your product's position within the Finnish market? Then Patient Dynamics is the ideal tool for you. Developed by Medaffcon, Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
“Renewable drug therapy challenges the current complex drug evaluation system,” states Lauri Pelkonen, a leading expert at the Ministry of Social Affairs and Health (STM). For this reason, the evaluation activity is being reformed to better respond to changes in the operating environment.
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
Principal Consultant
MSc (Economics)
+358 40 139 4001
jarmo.hahl@medaffcon.fi
Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.
Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.
“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.
Sales Lead
eMBA
+358 50 305 5963
tomi.vahevaara@medaffcon.fi
Tomi Vahevaara started working at Medaffcon in January 2017 as a Sales Director. He has been working in the pharmaceutical industry for over 35 years. Therefore, he has gained wide-ranging experience in international expert and managerial positions within the innovative pharmaceutical industry. Before joining Medaffcon, Tomi worked for ten years as the Managing Director of Eli Lilly for Finland, the Baltic States, and Poland.
Tomi has solid and wide-ranging expertise in different positions in the pharmaceutical field and is well connected in the entire health industry network. He serves as the Chairman of the Board of the Finnish Mutual Insurance Company for Pharmaceutical Injury Indemnities and as a Board Member in the Finnish Co-operative for Pharmaceutical Injury Indemnities. Tomi is particularly interested in the significant economic and investment opportunities for Finland and those companies working in the Finnish health industry.
Sr. Consultant
BBA
+358 40 355 6111
petri.maatta@medaffcon.fi
Petri joined Medaffcon in 2022 as a consultant. Petri holds extensive experience in the pharmaceutical industry especially in Market Access, sales and marketing. Before joining Medaffcon Petri worked in various managerial roles in the pharmaceutical industry which has provided him with a comprehensive understanding of the challenges and opportunities in the field. Petri conducted his BBA studies in the Netherlands and Finland providing him with a great basis to work in international organizations.
Petri’s extensive experience in the pharmaceutical industry and his background in business equip him with a unique perspective in the field of Life Science and commercialization of medicines in Finland. His main focus is on helping companies bring Life Science innovations and services to the Finnish market. Petri’s expertise in Market Access, sales and marketing as well as his deep understanding of the pharmaceutical industry provide Medaffcon’s team with valuable information as they provide customer solutions.
“Resource challenges alongside technological development and digitalization provide considerable opportunities to enhance healthcare in Finland. As data collection and digitalization develop, the effectiveness of health technologies can be demonstrated more precisely. While advanced health technologies and medicine offer more effective treatments, bringing them to the market require special know-how and understanding. Thus, companies, the research sector and governmental agencies should continue to further co-operation in effectively bringing health technologies and medicines to the market while simultaneously managing resource allocation in a rational manner.”